Last 738.15 INR
Change Today -7.05 / -0.95%
Volume 150.7K
GNP On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Open
741.70
Previous Close
745.20
Day High
749.90
Day Low
733.00
52 Week High
09/16/14 - 790.00
52 Week Low
11/27/13 - 487.60
Market Cap
200.2B
Average Volume 10 Days
622.9K
EPS TTM
20.01
Shares Outstanding
271.3M
EX-Date
07/10/14
P/E TM
36.9x
Dividend
2.00
Dividend Yield
0.27%
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GNP)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Managing Director, Chi...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study

Glenmark Pharmaceuticals announced that its first in class Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India. A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as detected by a standardized testing methodology. GRC 17536 was well-tolerated with no evidence of CNS or other drug related side effects. The Glenmark TRPA1 program includes indications in pain as well as respiratory. Inhaled doses of GRC 17536 are also being tested in a Phase 2A proof of concept study in patients with Chronic Cough.

Glenmark Pharmaceuticals Limited Approves Dividend for the Financial Year Ended 2013-2014

Glenmark Pharmaceuticals Limited approved Dividend of INR 2 per share of INR 1 each (200%) on the equity share capital of the company for the financial year ended 2013-2014.

Glenmark Pharmaceuticals Ltd. Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2014

Glenmark Pharmaceuticals Ltd. reported unaudited standalone and consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported standalone net profit of INR 1,039.34 million compared to INR 1,177.99 million for the quarter ended June 30, 2013. Basic and diluted earnings per share before and after extraordinary items were INR 3.83 against INR 4.34 for the previous corresponding quarter. Net sales/income from operations was INR 5,932.22 million against INR 5,079.78 million for the previous corresponding quarter. Profit from operations before other income, finance costs and exceptional items was INR 1,135.69 million against INR 1,247.47 million for the previous corresponding quarter. Profit from ordinary activities before tax was INR 1,217.57 million against INR 1,375.76 million for the previous corresponding quarter. For the quarter, the company reported consolidated net profit of INR 1,848.97 million compared to INR 1,305.55 million a year ago. Diluted earnings per share before and after extraordinary items were INR 6.81 against INR 4.75 for the previous corresponding quarter. Net sales/income from operations was INR 14,778.19 million against INR 12,378.82 million for the previous corresponding quarter. Profit from operations before other income, finance costs and exceptional items was INR 2,772.67 million against INR 2,129.08 million for the previous corresponding quarter. Profit from ordinary activities before tax was INR 2,326.11 million against INR 1,698.04 million for the previous corresponding quarter. The company delivered strong results backed by good performances by its India, Rest of the World, Europe and LATAM businesses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 738.15 INR -7.05

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ANI Pharmaceuticals Inc $28.06 USD -1.24
Impax Laboratories Inc $24.55 USD +0.02
Jubilant Life Sciences Ltd 168.85 INR -4.05
Lannett Co Inc $43.46 USD +2.11
Ranbaxy Laboratories Ltd 594.45 INR -8.05
View Industry Companies
 

Industry Analysis

GNP

Industry Average

Valuation GNP Industry Range
Price/Earnings 32.9x
Price/Sales 3.2x
Price/Book 6.6x
Price/Cash Flow 23.3x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.